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Introduction
Enhancing brain lesions are one of the most commonly
encountered abnormalities in routine conventional brain
scanning. These can be due to a variety of neoplastic,
infectious and vascular pathologies.1-3 In the West, after
excluding multiple sclerosis, these are mostly neoplastic
in aetiology. However, in developing countries, the
spectrum of aetiologies of multiple enhancing lesions of
the brain is likely to be different as infective pathologies
are more frequently encountered.4-6 These lesions most of
the time have similar appearances on routine non-
invasive conventional imaging techniques like Computed
Tomography (CT) scanning and Magnetic Resonance
Imaging (MRI). It is imperative to differentiate neoplastic
mass lesions from infective pathologies as management
and further treatment plan is entirely different in these
cases. Newer MRI techniques like spectroscopy and
diffusion-weighted imaging further help in reaching the
more likely diagnosis. MR spectroscopy (MRS) has the
potential for discerning the presence and relative amount
of various chemical metabolites in the brain and is
therefore a useful technique to further assess various
intracranial diseases.7,8
Initial in vivo brain MRS studies were done in the early
1980s and then its clinical effectiveness was further
recognised. MRS extends the diagnostic utility of the MR
brain examination beyond the typical structural images of
anatomy and provides another molecular dimension
based on biochemical information.9,10 The major brain
metabolites detected are Choline (Cho), Creatine (Cr), N-
acetyl aspartate (NAA), lactate, myo-inositol, glutamine,
glutamate, lipids, and the amino acids leucine and
alanine. Major differentials of enhancing cerebral lesions
are primary neoplastic lesion versus inflammatory and
infective lesions. Infective lesions like brain abscess
usually show reduced level of all major metabolites,
including Cho, Cr and NAA, while neoplastic lesions show
increased Cho peak with reduced NAA levels. Lipid/lactate
peak can be observed in both types of lesions, but more
commonly in necrotic lesions and abscess cavities. 
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Abstract
Objectives: To investigate the efficacy of magnetic resonance spectroscopy in differentiating various types of
neoplastic and non-neoplastic enhancing cerebral lesions.
Methods: The prospective study was conducted from January 2007 to December 2009 at the Department of
Radiology, Aga Khan University Hospital, Karachi. All patients with enhancing brain lesions on magnetic resonance
imaging who underwent magnetic resonance spectroscopy and a biopsy with histopathological analysis were
included in study. The lesions were categorised into neoplastic and non-neoplastic lesions on the basis of
spectroscopy findings. The sensitivity, specificity, positive predictive value, negative predictive value and diagnostic
accuracy of magnetic resonance spectroscopy were calculated. Predicted probabilities were computed and
comparison of median values of metabolites and their ratios was analysed using non-parametric Mann Whitney U
test to differentiate between neoplastic and non-neoplastic lesions. 
Results: Of the 102 patients enrolled, 78(76.5%) comprised the final study sample. There were 53(68%) male and
25(32%) female patients with an overall mean age of 40.21±17.69 years (range: 4-76 years). The mean overall size of
the lesion was 4.01±1.79cm, and 61(78%) lesions were neoplastic and 17(22%) were non-neoplastic. The sensitivity,
specificity, positive predictive value and negative predictive value and diagnostic accuracy of magnetic resonance
spectroscopy in differentiating neoplastic and non-neoplastic lesions were 90.16%, 64.70%, 90.16%, 64.70% and
78.20% respectively. A cut-off value of 2.55 of Choline/N-Acetyl Aspartate ratio depicted sensitivity of 70% in
differentiating the lesions. 
Conclusion: Magnetic resonance spectroscopy is a highly sensitive technique in addition to conventional magnetic
resonance imaging in characterising and differentiating between neoplastic and non-neoplastic cerebral lesions. 
Keywords: Spectroscopy, Functional imaging, Cancer, Neoplasm, Infections, Tuberculoma. (JPMA 64: 1141; 2014)
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Literature shows MRS is increasingly useful in studying
brain tumours, infections and various types of
inflammatory lesions.7-11 Recent reports regarding MRS
support its use as a powerful tool in grading of glioma and
also in distinguishing it from metastasis.12-16 Similarly,
tumour infiltration can occur in non-enhancing regions at
the periphery of the tumour and that these areas are most
of the time, sites of tumour recurrence after surgical
removal. MRS can show increased metabolism along with
loss of neuronal activity at these sites and can help in
diagnosing tumour recurrence. MRS is also being used to
avoid sampling errors and guide the most appropriate site
for obtaining a biopsy when residual tumour is
suspected.17,18 Radiation-induced necrosis versus
recurrent or residual tumour is yet another diagnostic
dilemma where MRS may be helpful.19 MRS also
complements conventional MR imaging in characterising
infectious lesions and being used to differentiate
between brain abscess and high-grade glioma. Similarly,
this tool can also be used to discriminate tuberculous
from pyogenic brain abscesses.20,21
The utility of MRS in various types of brain lesions has
been extensively studied all over the world. Very few
centres in Pakistan have the options of MRS in their MR
scanners and most of the cases are diagnosed on
conventional MR sequences, and the available resources
are very costly and not affordable or reachable for most of
the population. The current study was planned as the first
large-scale investigation in Pakistan. It aimed at looking
for the pattern of metabolites in enhancing brain lesions
in patients presenting at a tertiary care center and to
differentiate between various types of infective lesions on
the basis of the quantitative values and ratio of
metabolites, especially tuberculous versus non-
tuberculous or fungal infections.
Patients and Methods
The prospective study was conducted from January 2007
to December 2009 at the Department of Radiology, Aga
Khan University Hospital (AKUH), Karachi, after getting
approval from the institutional ethics review committee. 
All patients with enhancing brain lesions on MRI who
underwent MRS and a biopsy with histopathological
analysis were included in study. 
Those included came from inpatient wards, clinics and as
outpatient referrals. Those who were found to have
enhancing brain lesions on MRI were initially included.
Their history was taken on prescribed proforma. Informed
consent was taken from all the patients. Gadolinium was
used as intravenous contrast. All images were interpreted
on Leonardo software by two trained neuro-radiologists.
All scans were done on Siemens 1.5 Tesla MR Scanner
using head coil. Axial T1, T2, Sagittal T2, coronal Fluid
Attenuated Inversion Recovery (FLAIR) and post-contrast
axial, coronal and sagittal images were acquired. MRS was
performed through single and multi-voxel technique.
After water suppression, a point-resolved spectroscopy
(PRESS) technique was used for localisation and the
studies were obtained with TE and TR of 135 and 1500
respectively. 
Metabolites were plotted on the X axis on the MR
Spectrum in parts per million (ppm). The height of peak
on the Y axis indicated their relative concentrations.
Major metabolites were NAA which appears at 2.01ppm,
Cho at 3.22ppm, Cr at 3.02, lipid at 0.8 to 1.3ppm and
lactate at 1.32 to 1.33ppm. 
All the images were interpreted by two consultant
radiologists having experience in MRI interpretation,
including MRS. Final diagnosis was made on
histopathology results. On the basis of MRS findings,
lesions were categorised into neoplastic and non-
neoplastic lesions. 
After routine evaluation of the lesions on conventional
sequences, MR spectra were evaluated for presence and
integral values of metabolites, notably including NAA,
Cho, Cr and lipid/lactate. 
On MRS, lesions were categorised as neoplastic if there
was increased Cho and decreased NAA levels, and
increased Cho/Cr and Cho/NAA ratio. They were
considered non-neoplastic if there was decreased Cho, Cr
and NAA levels.8-11
Data was analysed using SPSS 19.0. Sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV), and diagnostic accuracy of MRS was calculated.
Median values of major metabolites and their ratio were
also calculated and comparisons of median values of
neoplastic and non-neoplastic enhancing lesions were
evaluated using Mann-Whitney U test to test for
significance at p<0.05. 
Sensitivity and specificity were also calculated for Cho,
Cho/Cr and Cho/NAA values to differentiate between
neoplastic and non-neoplastic lesions by computing
predicted probabilities. 
Results
Of the 102 patients initially enrolled, 24(23.5%) were
excluded due to non-availability of biopsy reports or
histopathology. As such, the final study sample comprised 
78(76.4%) cases. There were 53(68%) male and 25(32%)
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female patients with an overall mean age of 40.21±17.69
years (range: 4-76 years). The mean overall size of the
lesion was 4.01±1.79cm, and 61(78%) lesions were
neoplastic and 17(22%) were non-neoplastic on the basis
of MRS. Histopathological evaluation also showed
61(78%) neoplastic and 17(22%) non-neoplastic lesions,
but 55(90.1%) of 61 neoplastic lesions on MRS turned out
to be neoplastic on histopathology. Similarly 11(64.7) of
the 17 non-neoplastic lesions on MRS were diagnosed as
non-neoplastic on histopathology. Overall sensitivity,
specificity, PPV and NPV were 90.16%, 64.70%, 90.16%,
64.70% and diagnostic accuracy was 78.20%. 
Neoplastic lesions included various grades and types of
astrocytoma [35; 57.37%], metastatic lesions [6; 9.84%],
lymphoma [5; 8.19%], meningioma [7; 11.47%],
medulloblastoma [2; 3.27%], acoustic neuroma [2; 3.27%],
anaplastic ependymoma [2; 3.27%], Primitive
Neuroectodermal tumour (PNET) [1; 1.63%] and
haemangioblastoma [1; 1.63%].
Non-neoplastic infective/inflammatory lesions included
tuberculous granulamotous inflammation [10; 58.82%],
reactive glial tissue [4; 23.52%], fungal [2; 11.76%] and
pyogenic abscess [1; 5.88%].
False positive were granulomatous inflammation [2;
33.33%], reactive glial tissue [2; 33.33%], necrotic tissue [1;
16.66%] and fungal infection [1; 16.66%] on
histopathology. Similarly, false negative cases diagnosed
on histopathology as various types of astrocytoma [3;
50%], metastatic lesion [2; 33.33%] and anaplastic
ependymoma [1; 16.66%].
Median NAA value of neoplastic lesions was 0.39 and non-
neoplastic lesions of 0.54 (p<0.160). Cho level 2.15 was
significantly increased in neoplastic lesions compared to
non-neoplastic lesions of 1.03 (p<0.0001). Cr value in
neoplastic lesions was 0.58 compared to 0.55 in non-
neoplastic lesions (p<0.799). 
Cho/Cr ratio in neoplastic lesions was 3.44 and 1.89 in
non-neoplastic lesion (p<0.003). Similarly, Cho/NAA ratio
was 4.28 compared to 1.67 in non-neoplastic lesions
(p<0.0001). NAA/Cr ratio was 0.73 in neoplastic lesions
compared to 0.91 in non-neoplastic lesions (p=0.289).
Out of 10 tuberculous lesions on histopathology, 6 (60%)
were diagnosed as non-neoplastic lesions on MRS, while 4
(40%) were interpreted as neoplastic lesion. Similarly, 5
out of 7 (70%) non-tuberculous non-neoplastic lesions
were identified as non-neoplastic on MRS.
There were 24 cases of high grade gliomas and 11 low
grade gliomas. Mean Cho value in high-grade
astrocytoma was 2.36±1.15 compared to 1.65±1.03 in
low-grade gliomas. Mean Cho value in 6 metastatic
lesions was 1.67±1.47. NAA in high-grade astrocytoma
was 0.74±0.53 compared to 0.47±0.33 in low-grade
gliomas. NAA in metastatic lesions was 0.51±0.25. Cho/Cr
ratio in high-grade gliomas was 3.93±3.93 and 2.98±2.73
in low-grade gliomas. Cho/NAA and Cho/Cr ratio was
3.28±2.35 and 3.74±4.76 respectively in metastatic
lesions. A characteristic pattern for tuberculous lesions on
MRS could not be found.
Predicted probabilities were computed to look for the
best relationship between sensitivity and specificity.
Cho/NAA ratio of 2.55 and sensitivity of 70% was
significant (p<0.019). Mean Cho value of 1.44 and
sensitivity and specificity of 69% and 65% respectively
was also significant (p<0.002). Lipid/lactate peaks were
observed in 37 lesions. Out of these, 28(45.90%) were
identified in 61 lesions and 9(52.94%) in 17 non-
neoplastic lesions. Cut-off values of Cho/Cr, Cho/NAA and
NAA/Cr ratios in differentiating between neoplastic and
non-neoplastic lesions were also worked out (Table). 
Discussion
MRS provides a chemical profile of the cerebral lesions
that may facilitate the determination of the type of the
lesion. Radiologically detected brain lesions are classified
as neoplastic and non-neoplastic on the basis of certain
MRS criteria. MR Spectrum was obtained from the lesion
after placing an appropriate voxel over the area of
Vol. 64, No. 10, October 2014
Magnetic resonance spectroscopy of enhancing cerebral lesions: Analysis of 78 histopathology proven cases 1143
Table: Cut-off values of Cho/Cr, Cho/NAA and NAA/Cr ratios in differentiating
neoplastic and non-neoplastic lesions.
Positive if > Sensitivity [1- Specificity]
§Cho/Cr
1.2350 0.900 0.778
1.6400 0.800 0.667
1.96560 0.717 0.500
2.4350 0.617 0.444
^Cho/ NAA
1.3400 0.900 0.778
1.3800 0.900 0.722
1.4750 0.900 0.667
2.0150 0.800 0.556
2.0950 0.800 0.500
2.5150 0.700 0.444
2.5550 0.700 0.389
¤NAA/Cr
0.1000 0.967 0.944
0.4050 0.800 0.778
0.4900 0.700 0.722
§Cho/Cr: Choline to Creatine ratio
^Cho/ NAA: Choline to N-acetyl aspartate ratio
¤NAA/Cr: N-acetyl aspartate to Creatine ratio.
interest. Previous studies have extensively described the
role of MRS in differentiating various types of brain
lesions.7-21 The present study revalidates this technique as
highly sensitive in differentiating between neoplastic and
non-neoplastic brain lesions although it was not very
specific. Cho level was significantly increased in brain
tumours due to an increase in mitotic activity which is not
present in non-neoplastic lesions. Our study showed
median Cho levels of 2.15 in neoplastic lesions compared
to non-neoplastic lesions of 1.03 which makes it single
best marker to differentiate between thr two types of
brain lesions. Previous studies have also described the
mean Cho values in neoplastic and non-neoplastic
lesions.22,23 Similarly, significant increase in Cho/Cr and
Cho/NAA ratio were observed in neoplastic lesions which
were also reported in previous studies. The most
frequently studied chemical ratios used to distinguish
tumours from other brain lesions with MRS are Cho/Cr,
Cho/NAA and Lactate/Cr. Specifically, a Cho/NAA ratio
greater than 1 is considered to indicate a neoplasm.24
In our study, absolute NAA and Cr values did not show
statistical significance in differentiating neoplastic and
non-neoplastic brain lesions. Similarly, variance in NAA/Cr
ratio in neoplastic and non-neoplastic lesions was not
statistically significant. However, a study described
sensitivity and specificity of 64% and 69% in detecting
neoplastic lesion using NAA/Cr with a significant p value.23
Mean Cho value in high-grade astrocytoma was 2.36±1.15
compared to 1.65±1.03 in low-grade gliomas in our study.
Similarly Cho/Cr ratio in high-grade gliomas was
3.93±3.33 and 2.98±2.73 in low-grade gliomas. Literature
review also showed that mean Cho values and Cho/Cr and
Cho/NAA can also help in differentiating low-grade
gliomas and high-grade astrocytoma. One study reported
mean Cho/Cr ratio of 2.11±0.93 and 1.26±0.38 in high-
grade and low-grade gliomas.25 A study described mean
Cho/Cr ratio in high-grade gliomas and metastasis as
3.92±3.31 and 1.84±1.22 respectively.11 Another reported
that this method is useful in the differentiation of high-
and low-degree glial tumours with the Cho/Cr ratio being
higher than 1.56 in high-degree malignant tumours.26 Our
study also showed increased level of Cho and Cho/Cr in
high-grade glial tumours. No significant difference was
noted in mean values of Cho in high-grade glial tumours
and metastasis.
A study described Cho/Cr ratio of 1.55 or larger predicted
a malignant tumour with 93% sensitivity and 80%
specificity.25 In our study, Cho/NAA ratio of 2.55 and
above showed sensitivity of 70% in differentiating
between neoplastic and non-neoplastic lesions which is
in contrast with the earlier study. Our mean Cho value was
1.44 and sensitivity and specificity were 69% and 65%
respectively. An earlier study also reported the sensitivity
and specificity of the Cho/Cr ratio in detecting neoplasm
was 77% and 79% when the ratio was 1.97 or above to
differentiate between inflammatory lesions and
tumours.23 There is little consensus in literature regarding
actual integral value of Cho and Cho/Cr and Cho/NAA
ratio in reliably differentiating between neoplastic and
non-neoplastic lesions, and further studies need to be
done on larger scale.
Lipid/lactate peaks were observed in both neoplastic and
non-neoplastic lesions and was relatively non-specific in
differentiating between these entities. Similar results have
been reported in previous studies.20-22
We had 6 false positive and 6 false negative cases. Possible
explanation for this is site of the lesion and the placement
of voxel which can result in false analysis of the
metabolites.27 Lesions located near the base of the skull or
bone can result in increased noise which again leads to
incorrect results.11 The content of the lesion can also
result in false interpretation. High-grade necrotic tumour
can have metabolite contents similar to non-neoplastic
lesions with reduced Cho, Cr and NAA levels with high
levels of lipid/lactate peak. Similarly, invasive fungal
infection due to increased mitotic activity can produce
high levels of Cho with reduced NAA and Cr levels.28
There are a few limitations in our study. The sample size
was relatively small with only 17 cases of non-neoplastic
lesions with histopathological analysis not available in a
large number of patients who had to be excluded. This
could be due to the fact that non-neoplastic lesions were
usually medically treated rather than surgically and usual
follow-up was done in these types of cases rather than
invasive procedures. Although histological confirmation is
the gold standard, but the change in size and number of
lesions or stability over a period of a year is also a useful
alternative.
Conclusion
MRS is highly sensitive but relatively less specific
technique in differentiating between neoplastic and non-
neoplastic brain lesions. MRS is useful adjunct in
problematic cases and Cho, Cho/Cr and Cho/NAA ratios
are the best indicators in MRS for differentiating between
lesions, although no established demarcating values of
these metabolites and their ratios have been established
and further larger-scale studies are needed in this regard. 
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